Alexander Mansour, MBA
Advertisement
Articles by Alexander Mansour, MBA
The Centers for Medicare and Medicaid Services finalized a ruling that slashes reimbursement rates on drugs that qualify under the 340B program.
Advertisement
Latest Updated Articles
- Opinion: CMS 340B Reimbursement Cuts Cause Big Pharma Profits While Underserved Patients Lose
Published: January 4th 2018 | Updated:
Opinion: CMS 340B Reimbursement Cuts Cause Big Pharma Profits While Underserved Patients LosePublished: January 3rd 2018 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
November 2025 Pharmacy Policy Updates
2
Semaglutide Shows Direct Organ-Protective Benefits Beyond Weight Loss in HFpEF
3
We Can Do Better: Educating on Perimenopause and Menopause Is a Good Thing
4
Immune Synergy May Explain Why Some Patients Achieve Durable Remission With Cilta-Cel
5
